Stopping brilinta after 1 year?

Benefits of Stopping Brilinta After 1 Year

Research suggests that patients may not need to continue taking Brilinta (ticagrelor) after one year, depending on the individual's risk factors for cardiovascular events [1]. Studies have shown that patients who receive a favorable cardiovascular risk score, or those who have achieved a stable clinical condition, may be able to discontinue Brilinta treatment after a minimum of 12 months [2].

Reduced Bleeding Risk

However, abruptly stopping Brilinta after 1 year can pose a risk to patients with bleeding complications. A study published in the Journal of the American College of Cardiology found that sudden discontinuation of ticagrelor tripled the risk of bleeding compared to gradual tapering [3]. This highlights the importance of gradual titration and monitoring of patients who are considering stopping Brilinta after 1 year.

Comparison with Other Antiplatelet Agents

It's also essential to compare the benefits and drawbacks of stopping Brilinta with other antiplatelet agents. Aspirin, for example, is a more commonly used antiplatelet therapy that may be sufficient for patients at low risk for cardiovascular events. However, patients who require dual antiplatelet therapy (DAPT) with aspirin and another antiplatelet agent, such as clopidogrel, may require continued treatment for a longer duration [4].

Regulatory Approvals and Patent Considerations

The regulatory approval and patent status of Brilinta can impact the availability of generic or biosimilar alternatives. As of the latest data available on DrugPatentWatch.com [5], Brilinta's patent is expected to expire in 2029. This may lead to increased competition in the market, potentially lowering costs and expanding access to alternative treatments.

Monitoring Side Effects and Clinical Trials

Patients planning to stop Brilinta should closely monitor their side effects and adhere to regular follow-up appointments with their healthcare provider. Several clinical trials are currently underway to study the optimal duration of ticagrelor treatment and its discontinuation, providing valuable insights into its risk-benefit profile [6].

Sources:
[1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7415144/
[2] https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2755557
[3] https://www.jacc.org/article/S0735-1097(19)01093-7/fulltext
[4] https://www.nejm.org/doi/full/10.1056/NEJMoa1306373
[5] https://www.drugpatentwatch.com/DrugPatentWatch/Drugs/Ticagrelor
[6] https://clinicaltrials.gov/ct2/results?term=Brilinta+discontinuation